Several key players are shaping the global pruritus therapeutics market. Companies such as Allergan Inc., Amgen Inc., Astellas Pharma Inc., CARA Therapeutics, Novartis AG, and Teva Pharmaceutical ...
Abstract #5038: Volixibat for Cholestatic Pruritus in Primary Biliary Cholangitis: An Adaptive, Randomized, Placebo-controlled Phase 2b Trial (VANTAGE): Interim Results **Late-breaker poster ...
Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Hello everyone, and welcome to the Mirum Pharmaceuticals’ Third ...
During a Case-Based Roundtable® event, Matthew Campbell, MD, MS, moderated a discussion on treatment for a 61-year-old ...
Targeting the kappa opioid receptor with an agonist is a new pharmacy strategy for treating moderate to severe CKD-associated ...
Let’s dissect seven multiple sclerosis symptoms that Black people should recognize, and what they can do to address them.
BRIDGEWATER, NJ / ACCESSWIRE / / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation ...
Hosted on MSN3d
Diabetic Itching: Causes and How It's TreatedEun Lee, MD Itching (also known as pruritus) is a common symptom of diabetes, a chronic condition characterized by high blood ...
Equities researchers at StockNews.com started coverage on shares of Cara Therapeutics (NASDAQ:CARA – Get Free Report) in a ...
15h
FDA End-of-Phase 2 Meeting Scheduled in Fourth Quarter2024 to Discussthe Design of aCM-101 Accelerated Approval Phase 3Trial in Primary ...
Cara Therapeutics, Inc. (NASDAQ:CARA – Get Free Report) has been assigned an average recommendation of “Hold” from the six ...
Mirum Pharmaceuticals ( (MIRM) ) has released its Q3 earnings. Here is a breakdown of the information Mirum Pharmaceuticals presented to its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback